Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurocrine Biosciences Inc (Nasdaq: NBIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, publicly traded biopharmaceutical company, Neurocrine Biosciences reports its financial performance, material events and key corporate developments through forms such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports.
In its recent Form 8-K filings, Neurocrine Biosciences has reported quarterly financial results, including net product sales for INGREZZA and CRENESSITY, research and development and selling, general and administrative expenses, and net income. These filings often incorporate press releases that discuss revenue trends, non-GAAP financial measures, R&D investment in programs such as osavampator and direclidine, and updates on collaborations. Other 8-K items may cover executive and board-related matters, such as amendments to employment agreements and changes in key leadership roles.
On this page, investors can review the full text of Neurocrine Biosciences’ periodic reports to understand how the company describes its business, risk factors, product portfolio and pipeline. The annual Form 10-K typically includes detailed sections on therapeutic focus areas like tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as discussion of the company’s neuroscience and endocrinology research strategy. Quarterly Form 10-Q filings update these disclosures and provide interim financial statements.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, helping readers quickly identify changes in revenue composition, R&D spending, collaboration milestones and other material items. Users can also monitor real-time 8-K updates for new clinical data announcements, financing activities or governance changes, and access Form 4 insider transaction reports to see how company insiders are trading NBIX shares, when such filings are available.
Whether you are evaluating Neurocrine Biosciences’ exposure to specific therapeutic areas, following its investment in late-stage programs like osavampator and direclidine, or comparing GAAP and non-GAAP results, this filings page offers a structured view of the company’s official SEC record with tools that make complex disclosures easier to interpret.
Neurocrine Biosciences reports its full-year 2025 results and business overview, highlighting strong growth from key neuroscience drugs. INGREZZA net product sales reached $2.51 billion in 2025, up from $2.31 billion in 2024 and $1.84 billion in 2023, while CRENESSITY generated $301.2 million in its first full launch year.
The company is expanding a U.S. sales force of about 600 people and plans to add more INGREZZA and CRENESSITY representatives by the end of the first quarter of 2026. Late-stage programs include Phase 3 trials for osavampator in major depressive disorder and direclidine in schizophrenia, with initial topline data expected in 2027.
Neurocrine emphasizes a broad pipeline across psychiatry, neurology, endocrinology and metabolic disease, backed by extensive patent protection. The company also discloses a civil investigative demand from the U.S. Department of Justice related to INGREZZA sales and marketing, noting it is cooperating and that the ultimate outcome is uncertain.
Neurocrine Biosciences reported strong growth for the fourth quarter and full year 2025. Total revenues reached $805.5 million in Q4 and $2.86 billion for 2025, up from $2.36 billion in 2024, driven mainly by its neurology portfolio.
INGREZZA generated net product sales of $657.5 million in Q4 and $2.51 billion for 2025, with single‑digit growth as prescription volumes rose but were partially offset by lower net price from new formulary investments. CRENESSITY contributed $135.3 million in Q4 and $301.2 million for 2025 as a new growth driver.
GAAP net income increased to $153.7 million in Q4 and $478.6 million for 2025, while Non‑GAAP net income was $194.6 million in Q4 and $654.5 million for the year. Cash, cash equivalents, and marketable securities totaled $2.54 billion at December 31, 2025, supporting heavy R&D and commercial investment.
For 2026, the company guides INGREZZA net product sales to $2.7–$2.8 billion, and plans GAAP R&D spending of $1.2–$1.25 billion and GAAP SG&A of $1.38–$1.40 billion as it advances Phase 3 programs in depression and schizophrenia and continues the CRENESSITY launch.
Neurocrine Biosciences Chief Corp. Affairs Officer David W. Boyer reported routine equity compensation activity. On January 31, 2026, 2,096 restricted stock units converted into the same number of Neurocrine Biosciences common shares at $0 exercise price.
To cover tax withholding on this RSU vesting, the company withheld 1,189 shares of common stock at $136.06 per share, and no shares were sold in the market. Following these transactions, Boyer directly owned 4,713 shares of Neurocrine Biosciences common stock. The underlying RSU grant, originally awarded on January 31, 2022, completed its final vesting tranche of 2,096 shares on the same date.
Neurocrine Biosciences’ Chief Commercial Officer Eric Benevich reported routine equity compensation activity. On January 31, 2026, 2,294 restricted stock units vested and converted into common shares at an exercise price of $0, increasing his direct holdings before tax withholding.
To cover taxes on the vesting, the company withheld 1,292 common shares at $136.06 per share, and no shares were sold in the market. After these transactions, Benevich directly owned 52,755 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported equity compensation activity involving company stock. On January 31, 2026, 2,437 restricted stock units converted into an equal number of Neurocrine common shares at an exercise price of $0.
To cover tax withholding on this RSU vesting, 1,368 common shares were withheld by Neurocrine at a price of $136.06 per share; no shares were sold on the market. After these transactions, Abernethy directly owned 37,097 common shares, which include 218 shares purchased through the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported RSU vesting and tax withholding transactions. On January 31, 2026, 1,741 restricted stock units converted into the same number of common shares at $0 exercise price. To cover taxes, 997 shares of common stock were withheld at $136.06 per share, and no shares were sold on the market.
After these transactions, Cooke beneficially owned 27,602 shares of Neurocrine common stock, including 25,738 shares held by the Cooke Family Trust of 2004, over which she has voting and investment power. Each RSU represents the right to receive one share of common stock.
Neurocrine Biosciences’ Chief Regulatory Officer, Ingrid Delaet, reported routine equity compensation activity. On January 31, 2026, 801 restricted stock units vested and were converted into 801 shares of common stock at an exercise price of $0.
To cover tax withholding on this vesting, 475 shares were withheld by the company at $136.06 per share, as noted in the footnotes, and no shares were sold on the market. After these transactions, Delaet directly owned 5,056 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Executive Officer Kyle Gano reported routine equity compensation activity. On January 31, 2026, 2,927 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0, reflecting previously granted stock awards.
On the same date, 1,580 common shares were withheld by Neurocrine Biosciences at a price of $136.06 per share to cover tax withholding obligations related to this vesting, and the filing states that no shares were sold. Following these transactions, Gano directly owned 141,754 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences director Kevin Charles Gorman reported routine equity compensation activity. On January 31, 2026, 5,142 restricted stock units converted into the same number of Neurocrine common shares at $0 exercise price. To cover taxes on this vesting, 2,845 shares were withheld by the company at $136.06 per share, and no shares were sold on the market.
After these transactions, Gorman beneficially owned 516,893 common shares, held by the Gorman and Blais Family Trust, over which he has voting and investment power. The vesting completed an RSU grant originally awarded on January 31, 2022.
On January 31, 2026, Neurocrine Biosciences Chief Legal Officer Darin Lippoldt had 2,373 restricted stock units (RSUs) convert into common stock at an exercise price of $0. Each RSU represents the right to receive one share of common stock.
To satisfy tax withholding on this RSU vesting, the company withheld 1,335 shares of common stock at a price of $136.06 per share. The company states that no shares were sold in the market. Following these transactions, Lippoldt directly owned 47,792 shares of Neurocrine Biosciences common stock.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
